Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · IEX Real-Time Price · USD
7.05
+0.01 (0.14%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Monte Rosa Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Net Income
-135.35-108.5-73.96-35.88-7.74
Depreciation & Amortization
6.228.562.130.540.07
Share-Based Compensation
16.6711.665.20.350
Other Operating Activities
68.66-4.197.2611.941.5
Operating Cash Flow
-43.8-92.47-59.36-23.05-6.17
Capital Expenditures
-18.98-12.8-9.65-3.39-1.39
Change in Investments
107.78-206.42000
Investing Cash Flow
88.8-219.22-9.65-3.39-1.39
Share Issuance / Repurchase
2.6120.47237.900
Debt Issued / Paid
00000.75
Other Financing Activities
24.88-139.6660.0614.25
Financing Cash Flow
27.4920.47377.5660.0615
Net Cash Flow
72.49-291.22308.5533.627.44
Free Cash Flow
-62.78-105.27-69.02-26.44-7.56
Free Cash Flow Per Share
-1.22-2.23-2.76-17.43-1.51
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).